Masters in neurological disease treatments, may appear to be an overstatement, it is not. We have proven our abilities through development programs with big pharma partners that include Boehringer Ingelheim, Pfizer, Wyeth and GlaxoSmithKline.


  • PDE10 inhibitor in development to treat Schizophrenia and Huntington’s disease

Discovery Platform Projects

  • NMDA-receptor Negative Allosteric Modulators (NAMs) for Treatment Resistant Depression and Major Depressive Disorder
  • Long Term Effective GABAA Positive Allosteric Modulators (LT GABAA PAMs): novel sub-type selective GABAA receptor modulators to treat refractory Epilepsy and Autism spectrum disorders
  • Novel ALS treatments from a Patient-to-screen phenotypic discovery platform that integrates patient derived induced pluripotent stem cells (iPSCs) into the screening and profiling process